TOKYO, Japan, September 4, 2025 - (JCN Newswire via SeaPRwire.com) – Honda Motor Co., Ltd. (Honda) will begin sales in Japan of the all-new Prelude tomorrow, on September 5, 2025.Inspired by the image of gliders soaring freely and boundlessly through the open sky, Honda developed the all-new Prelude under the grand concept of “Unlimited Glide,” striving for a vehicle that evokes the uplifting sensation of gliding gracefully through the air and extraordinary experience that people do not have in their everyday lives. Equipped with a further advanced e:HEV, original Honda hybrid system, this model will become the “prelude” for future Honda specialty sports models in the electrified era.All-new PreludeAll-new Prelude information website: https://www.honda.co.jp/PRELUDE/ (Japanese)Sales plan (monthly, in Japan): 300 unitsKey features of all-new PreludeExterior designThe all-new Prelude features a low, sharp front nose and smooth, yet expressive body lines, which contribute to the uplifting sensation of gliding through the air, as well as a low and wide stance that evokes a sense of dynamic driving. The headlight design expresses the soaring ...

Iwakuni City, Yamaguchi Prefecture, September 4, 2025 - (JCN Newswire via SeaPRwire.com) - Mazda Motor Corporation (Mazda) today signed an agreement with Yamaguchi Prefecture and Iwakuni City regarding the construction of the "Mazda Motor Corporation Iwakuni Plant," a new module pack plant for automotive cylindrical lithium-ion battery cells in Iwakuni City, Yamaguchi Prefecture, as announced in January this year. Based on this agreement, construction will commence in November this year, with the aim of starting plant operations in fiscal year 2027. The Iwakuni Plant will be Mazda's first new domestic plant since the start of operations at the Hofu No.2 Plant in 1992.Mazda is promoting electrification through its multi-solution approach to flexibly respond to diversifying customer needs and changing environmental regulations globally. The Iwakuni Plant will play an important role as a foundation supporting the global expansion of electrified products. This plant will assemble modules of automotive cylindrical lithium-ion battery cells sourced from Panasonic Energy Co., Ltd., and package them into battery packs. The plant aims to create a safe, secure, and comfortable workplace...

TOKYO, Japan, September 4, 2025 - (JCN Newswire via SeaPRwire.com) — NEC Corporation (NEC; TSE: 6701) today announced that it will begin a proof of concept (PoC) for introducing an Earthquake Early Warning System (EEWS) in Colombia. This follows NEC’s selection to undertake the "Project for Conducting a Feasibility Study on the Introduction of ICT-Based Early Earthquake Detection and Analysis Technology in the Republic of Colombia," for which Japan’s Ministry of Internal Affairs and Communications had issued a public solicitation for proposals.With the ultimate goal of providing an EEWS overseas for the first time, NEC plans to conduct this PoC in Colombia between September 2025 and March 2026 to verify the effectiveness of the EEWS and identify any potential issues.The role of EEWS in earthquake early warningsBackgroundColombia is a seismically active nation located along the circum-Pacific Ring of Fire. Extensive human and material damage were reported following a magnitude 6.2 earthquake in Colombia’s Department of Quindio in January 1999 and another that shook the nation’s capital of Bogota in August 2023 with a magnitude of 6.3. Since then, c...

TOKYO, September 4, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the company will deliver a total of 11 presentations, including clinical data on the selective orexin 2 receptor agonist (OX2R)E2086 and the latest findings on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO®) at the World Sleep Congress (World Sleep 2025) to be held in Singapore from September 5 to 10.Key presentations include results from the Phase Ib clinical study exploring the efficacy (Proof of Mechanism) of E2086 in people diagnosed with narcolepsy type 1 (NT1) and the Phase IV clinical study(SELENADE Study) investigating the effect of lemborexant in people whose insomnia was comorbid with depressive episodes of major depressive disorder and bipolar disorder (Poster 3-133). The company will also host a symposium introducing the latest evidence on lemborexant in Asia.Eisai considers neurology, including sleep disorders such as insomnia and narcolepsy, as a therapeutic area of focus. Eisai strives to create innovative products in therapeutic areas with high unmet medical needs a...